Anacor Pharmaceuticals, Inc. Announces Successful Completion of Pre-NDA Communications With the FDA for Tavaborole

Published: May 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed its pre-NDA (New Drug Application) communications with the Food and Drug Administration (FDA) related to tavaborole, its drug candidate for the topical treatment of onychomycosis. In its pre-NDA communications, Anacor achieved concurrence from the FDA on the content and format of the proposed NDA for tavaborole including required data related to safety, efficacy, manufacturing and packaging. Anacor remains on schedule to file the NDA in mid-2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news